MA51625B1 - Procédé de production de modulateurs de somatostatine - Google Patents
Procédé de production de modulateurs de somatostatineInfo
- Publication number
- MA51625B1 MA51625B1 MA51625A MA51625A MA51625B1 MA 51625 B1 MA51625 B1 MA 51625B1 MA 51625 A MA51625 A MA 51625A MA 51625 A MA51625 A MA 51625A MA 51625 B1 MA51625 B1 MA 51625B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- modulators
- somatostatin modulators
- producing somatostatin
- producing
- Prior art date
Links
- 102000005157 Somatostatin Human genes 0.000 title abstract 3
- 108010056088 Somatostatin Proteins 0.000 title abstract 3
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract 3
- 229960000553 somatostatin Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Eye Examination Apparatus (AREA)
- Optical Communication System (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des composés qui sont des modulateurs de la somatostatine, des procédés de production desdits composés, des compositions pharmaceutiques et des médicaments comprenant lesdits composés, ainsi que des procédés d'utilisation de ces composés dans le traitement d'états pathologiques, de maladies ou de troubles qui peuvent tirer avantage de la modulation de l'activité de la somatostatine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862618538P | 2018-01-17 | 2018-01-17 | |
| PCT/US2019/013844 WO2019143718A1 (fr) | 2018-01-17 | 2019-01-16 | Procédé de production de modulateurs de somatostatine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA51625A MA51625A (fr) | 2021-04-21 |
| MA51625B1 true MA51625B1 (fr) | 2022-07-29 |
Family
ID=67213594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA51625A MA51625B1 (fr) | 2018-01-17 | 2019-01-16 | Procédé de production de modulateurs de somatostatine |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10464918B2 (fr) |
| EP (2) | EP4092018A1 (fr) |
| JP (2) | JP7113900B2 (fr) |
| KR (1) | KR102462586B1 (fr) |
| CN (1) | CN111868049B (fr) |
| AU (1) | AU2019209469B2 (fr) |
| CA (1) | CA3088658A1 (fr) |
| DK (1) | DK3740475T3 (fr) |
| EA (1) | EA202091559A1 (fr) |
| ES (1) | ES2923529T3 (fr) |
| HR (1) | HRP20220852T1 (fr) |
| HU (1) | HUE059184T2 (fr) |
| IL (1) | IL276029B2 (fr) |
| LT (1) | LT3740475T (fr) |
| MA (1) | MA51625B1 (fr) |
| MD (1) | MD3740475T2 (fr) |
| MX (1) | MX2020007586A (fr) |
| PL (1) | PL3740475T3 (fr) |
| PT (1) | PT3740475T (fr) |
| RS (1) | RS63387B1 (fr) |
| SG (1) | SG11202006838VA (fr) |
| SI (1) | SI3740475T1 (fr) |
| TW (1) | TWI823891B (fr) |
| UA (1) | UA127355C2 (fr) |
| WO (1) | WO2019143718A1 (fr) |
| ZA (1) | ZA202004497B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109715612B (zh) | 2016-07-14 | 2022-09-16 | 克林提克斯医药股份有限公司 | 促生长素抑制素调节剂及其用途 |
| WO2019023278A1 (fr) | 2017-07-25 | 2019-01-31 | Crinetics Pharmaceuticals, Inc. | Modulateurs de la somatostatine et utilisations de ces derniers |
| HRP20220852T1 (hr) | 2018-01-17 | 2022-10-14 | Crinetics Pharmaceuticals, Inc. | Postupak za izradu modulatora somatostatina |
| MX2023002761A (es) * | 2020-09-09 | 2023-04-03 | Crinetics Pharmaceuticals Inc | Formulaciones de un modulador de somatostatina. |
| CN113214050B (zh) * | 2021-05-15 | 2022-07-19 | 宁夏忠同生物科技有限公司 | 一种合成2,3,5,6-四氟苯酚的方法 |
| IL314054A (en) * | 2022-01-11 | 2024-09-01 | Crinetics Pharmaceuticals Inc | Uses of a somatostatin modulator to treat carcinoid syndrome |
| WO2023238112A1 (fr) | 2022-06-10 | 2023-12-14 | Assia Chemical Industries Ltd. | Formes à l'état solide de paltusotine et leur procédé de préparation |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1035154A (en) | 1910-05-16 | 1912-08-13 | Ernest G Clark | Machine for rectifying perforated music and masters. |
| US1046491A (en) | 1910-08-24 | 1912-12-10 | Alfred Randolph | Gas-engine. |
| FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| WO2003045920A1 (fr) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | Composes 4-aminoquinoleines |
| PL372295A1 (en) | 2002-02-04 | 2005-07-11 | F.Hoffmann-La Roche Ag | Quinoline derivatives as npy antagonists |
| WO2005024416A1 (fr) | 2003-09-05 | 2005-03-17 | Binghe Wang | Composes rapporteurs fluorescents de l'acide boronique hydrosolubles et leurs utilisations |
| EP1773343A4 (fr) | 2004-07-13 | 2009-05-13 | Glaxo Group Ltd | Agents antibactériens |
| AU2007309708A1 (en) | 2006-03-13 | 2008-05-02 | Merck Sharp & Dohme Corp. | Somatostatin agonists |
| GB0818241D0 (en) | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
| CA2806332C (fr) | 2010-07-30 | 2017-11-14 | Oncotherapy Science, Inc. | Derives de quinoline et inhibiteurs de melk les contenant |
| US9884828B2 (en) | 2011-05-23 | 2018-02-06 | Imago Pharmaceuticals, Inc. | Substituted cinnolines as inhibitors of LRRK2 kinase activity |
| US20140228417A1 (en) * | 2011-10-05 | 2014-08-14 | Mapi Pharma Ltd. | Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids |
| EP2871179A4 (fr) | 2012-07-03 | 2016-03-16 | Ono Pharmaceutical Co | Composé ayant une activité agoniste sur un récepteur de la somatostatine, et leur utilisation à des fins médicales |
| AU2013331505A1 (en) | 2012-10-16 | 2015-04-30 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of ROR-gamma-t |
| CA2925651A1 (fr) * | 2013-09-30 | 2015-04-02 | Ono Pharmaceutical Co., Ltd. | Compose ayant une activite agoniste sur les recepteurs de la somatostatine et son utilisation medicale |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| WO2017003723A1 (fr) | 2015-07-01 | 2017-01-05 | Crinetics Pharmaceuticals, Inc. | Modulateurs de la somatostatine et leurs utilisations |
| WO2017003724A1 (fr) * | 2015-07-01 | 2017-01-05 | Crinetics Pharmaceuticals, Inc. | Modulateurs de somatostatine et leurs utilisations |
| CN109715612B (zh) | 2016-07-14 | 2022-09-16 | 克林提克斯医药股份有限公司 | 促生长素抑制素调节剂及其用途 |
| HRP20220852T1 (hr) | 2018-01-17 | 2022-10-14 | Crinetics Pharmaceuticals, Inc. | Postupak za izradu modulatora somatostatina |
-
2019
- 2019-01-16 HR HRP20220852TT patent/HRP20220852T1/hr unknown
- 2019-01-16 RS RS20220660A patent/RS63387B1/sr unknown
- 2019-01-16 CA CA3088658A patent/CA3088658A1/fr active Pending
- 2019-01-16 EP EP22168295.8A patent/EP4092018A1/fr not_active Withdrawn
- 2019-01-16 SI SI201930277T patent/SI3740475T1/sl unknown
- 2019-01-16 US US16/249,729 patent/US10464918B2/en active Active
- 2019-01-16 ES ES19740733T patent/ES2923529T3/es active Active
- 2019-01-16 JP JP2020538675A patent/JP7113900B2/ja active Active
- 2019-01-16 PL PL19740733.1T patent/PL3740475T3/pl unknown
- 2019-01-16 MA MA51625A patent/MA51625B1/fr unknown
- 2019-01-16 KR KR1020207023546A patent/KR102462586B1/ko active IP Right Grant
- 2019-01-16 EA EA202091559A patent/EA202091559A1/ru unknown
- 2019-01-16 CN CN201980019970.7A patent/CN111868049B/zh active Active
- 2019-01-16 PT PT197407331T patent/PT3740475T/pt unknown
- 2019-01-16 DK DK19740733.1T patent/DK3740475T3/da active
- 2019-01-16 AU AU2019209469A patent/AU2019209469B2/en active Active
- 2019-01-16 MD MDE20201200T patent/MD3740475T2/ro not_active IP Right Cessation
- 2019-01-16 EP EP19740733.1A patent/EP3740475B1/fr active Active
- 2019-01-16 WO PCT/US2019/013844 patent/WO2019143718A1/fr unknown
- 2019-01-16 IL IL276029A patent/IL276029B2/en unknown
- 2019-01-16 HU HUE19740733A patent/HUE059184T2/hu unknown
- 2019-01-16 SG SG11202006838VA patent/SG11202006838VA/en unknown
- 2019-01-16 LT LTEPPCT/US2019/013844T patent/LT3740475T/lt unknown
- 2019-01-16 UA UAA202004625A patent/UA127355C2/uk unknown
- 2019-01-16 MX MX2020007586A patent/MX2020007586A/es unknown
- 2019-01-17 TW TW108101800A patent/TWI823891B/zh active
- 2019-10-03 US US16/592,595 patent/US10889561B2/en active Active
-
2020
- 2020-07-21 ZA ZA2020/04497A patent/ZA202004497B/en unknown
- 2020-12-09 US US17/116,728 patent/US20210087165A1/en not_active Abandoned
-
2022
- 2022-07-26 JP JP2022118926A patent/JP2022166016A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51625B1 (fr) | Procédé de production de modulateurs de somatostatine | |
| MX2022001874A (es) | Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos. | |
| MA46018A (fr) | Activateurs d'édition du génome | |
| MA44861B1 (fr) | Modulateurs de la voie de réponse intégrée au stress | |
| MA53861B1 (fr) | Modulateurs de promédicaments de la voie de réponse intégrée au stress | |
| MA47392A1 (fr) | Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques | |
| MA54231A (fr) | Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine | |
| MA29931B1 (fr) | Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (flap) | |
| MA31764B1 (fr) | Composés et compositions en tant que modulateurs de l'activité de gpr119 | |
| BR112019000692A2 (pt) | moduladores de somatostatina e usos destes | |
| NZ757081A (en) | Somatostatin modulators and uses thereof | |
| MA30462B1 (fr) | Composes de pyridylamide antagonistes des canaux calciques de type t | |
| Post et al. | Developmental psychobiology of cyclic affective illness: Implications for early therapeutic intervention | |
| MA28660B1 (fr) | Composes et compositions en tant que modulateurs de ppar | |
| TN2012000073A1 (fr) | Derives des l-(piperidine-4-yl) pyrazole servant de modulateurs de gpr119 | |
| MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
| TW200602330A (en) | Compounds and compositions as PPAR modulators | |
| MA39359A1 (fr) | Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés | |
| BR112021019070A2 (pt) | Ligantes de pseudoquinase tyk2 | |
| MA30720B1 (fr) | Analogues de 2-phenoxypyrimidinone | |
| ATE284693T1 (de) | Verwendung von dopamin-d 3-rezeptorantagonisten zur herstellung von arzneimittel für die behandlung von nierenfunktionsstörungen | |
| MA53765A1 (fr) | Tubulysines et conjugués tubulysines-protéines | |
| MX2022009762A (es) | Moduladores del purinorreceptor 3 p2x (p2x3). | |
| BR112022000855A2 (pt) | Moduladores de nlrp3 | |
| MX2022007439A (es) | Antagonistas de piperidina del receptor de melanocortina subtipo 2 (mc2r) sustituidos con gem y usos de los mismos. |